News >

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

Gina Columbus @ginacolumbusonc
Published: Monday, Mar 04, 2019

Scot Ebbinghaus, MD

Scot Ebbinghaus, MD

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for a new extended dosing schedule for pembrolizumab (Keytruda) for all of the PD-1 inhibitor’s monotherapy indications in the European Union.1

The recommendation supports a new suggested dose of single-agent pembrolizumab at 400 mg every 6 weeks delivered as an intravenous (IV) infusion over 30 minutes. If approved by the European Commission, the every-6-weeks dose would be available in addition to the currently indicated dose of 200 mg every 3 weeks that is infused over 30 minutes.

The European Commission will now review the CHMP’s opinion, and a final decision on a marketing authorization is expected in the second quarter of 2019, according to Merck, the developer of the checkpoint inhibitor.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x